{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T08:31:37Z","timestamp":1788078697626,"version":"build-2784847793"},"reference-count":43,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T00:00:00Z","timestamp":1643068800000},"content-version":"vor","delay-in-days":299,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016016","name":"Gilead Sciences Europe Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016016","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Iberoamericana de Micolog\u00eda"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.riam.2021.04.004","type":"journal-article","created":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T02:30:51Z","timestamp":1626748251000},"page":"42-46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Antif\u00fangicos de uso sist\u00e9mico"],"prefix":"10.1016","volume":"38","author":[{"given":"Inmaculada","family":"Quiles-Melero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Garc\u00eda-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.riam.2021.04.004_bib0220","doi-asserted-by":"crossref","first-page":"e01735","DOI":"10.1128\/AAC.01735-19","article-title":"Fosmanogepix (APX001) is effective in the treatment of immunocompromised mice infected with invasive pulmonary scedosporiosis or disseminated fusariosis","volume":"64","author":"Alkhazraji","year":"2020","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.riam.2021.04.004_bib0225","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.cmi.2020.06.007","article-title":"How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European committee on antimicrobial susceptibility testing (EUCAST)","volume":"26","author":"Arendrup","year":"2020","journal-title":"Clin Microbiol Infect."},{"key":"10.1016\/j.riam.2021.04.004_bib0230","doi-asserted-by":"crossref","first-page":"S445","DOI":"10.1093\/infdis\/jix131","article-title":"Multidrug-Resistant Candida: Epidemiology, molecular mechanisms, and treatment","volume":"216","author":"Arendrup","year":"2017","journal-title":"J Infect Dis."},{"key":"10.1016\/j.riam.2021.04.004_bib0235","first-page":"B4698","article-title":"Candida and candidaemia. Susceptibility and epidemiology","volume":"60","author":"Arendrup","year":"2013","journal-title":"Dan Med J."},{"key":"10.1016\/j.riam.2021.04.004_bib0240","first-page":"43","article-title":"Molecular identification of Fusarium species complex isolated from clinical samples and its antifungal susceptibility patterns","volume":"5","author":"Bansal","year":"2019","journal-title":"Curr Med Myco."},{"key":"10.1016\/j.riam.2021.04.004_bib0245","first-page":"e01811","article-title":"Name changes for fungi of medical importance, 2018-2019","volume":"59","author":"Borman","year":"2020","journal-title":"J Clin Microbiol."},{"key":"10.1016\/j.riam.2021.04.004_bib0250","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1093\/jac\/dkaa185","article-title":"In vitro interaction of isavuconazole and anidulafungin against azole-susceptible and azole-resistant Aspergillus fumigatus isolates","volume":"75","author":"Buil","year":"2020","journal-title":"J Antimicrob Chemother."},{"key":"10.1016\/j.riam.2021.04.004_bib0255","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1093\/jac\/dku518","article-title":"Emergence of multiple resistance profiles involving azoles, echinocandins and amphotericin B in Candida glabrata isolates from a neutropenia patient with prolonged fungaemia","volume":"70","author":"Cho","year":"2015","journal-title":"J Antimicro Chemother."},{"key":"10.1016\/j.riam.2021.04.004_bib0260","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1097\/QCO.0000000000000411","article-title":"Emerging multidrug-resistant Candida species","volume":"30","author":"Colombo","year":"2017","journal-title":"Curr Opin Infect Dis."},{"key":"10.1016\/j.riam.2021.04.004_bib0265","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1128\/AAC.50.3.917-921.2006","article-title":"Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi","volume":"50","author":"Cuenca-Estrella","year":"2006","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.riam.2021.04.004_bib0270","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1128\/JCM.01190-13","article-title":"Isavuconazole activity against Aspergillus lentulus, Neosartorya udagawae and Cryptococcus gattii, emerging fungal pathogens with reduced azole susceptibility","volume":"51","author":"Datta","year":"2013","journal-title":"J Clin Microbiol."},{"key":"10.1016\/j.riam.2021.04.004_bib0275","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s11046-017-0141-9","article-title":"Activity of combined antifungal agents against Multidrug-Resistant Candida glabrata strains","volume":"182","author":"Denardi","year":"2017","journal-title":"Mycopathologia."},{"key":"10.1016\/j.riam.2021.04.004_bib0280","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1128\/JCM.41.8.3623-3626.2003","article-title":"Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi","volume":"41","author":"Diekema","year":"2003","journal-title":"J Clin Microbiol."},{"key":"10.1016\/j.riam.2021.04.004_bib0285","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1128\/JCM.36.10.2950-2956.1998","article-title":"Comparison of in vitro activities of the new triazole Sch56592 and the echinocandins mk-0991 (l-743,872) and ly303366 against opportunistic filamentous and dimorphic fungi and yeasts","volume":"36","author":"Espinel-Ingroff","year":"1998","journal-title":"J Clin Microbiol."},{"key":"10.1016\/j.riam.2021.04.004_bib0290","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1128\/AAC.01512-07","article-title":"In vitro antifungal activities of isavuconazol (BAL4815), voriconazole, and fluconazole against 1007 isolates of zygomycete Candida, Aspergillus, Fusarium and Scedosporium species","volume":"52","author":"Guinea","year":"2008","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.riam.2021.04.004_bib0295","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3314\/mmj.18.004","article-title":"Role of FKS Gene in the susceptibility of pathogenic fungi to echinocandins","volume":"59","author":"Hori","year":"2018","journal-title":"Med Mycol J."},{"key":"10.1016\/j.riam.2021.04.004_bib0300","doi-asserted-by":"crossref","first-page":"6934","DOI":"10.1128\/AAC.03261-14","article-title":"In vitro combination of isavuconazole with micafungin or amphotericin B deoxycholate against medically important molds","volume":"58","author":"Katragkou","year":"2014","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.riam.2021.04.004_bib0305","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1086\/651263","article-title":"Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database","volume":"50","author":"Kontoyiannis","year":"2010","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.riam.2021.04.004_bib0310","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1128\/AAC.05910-11","article-title":"Species-specific antifungal susceptibility patterns of Scedosporium and Pseudallescheria species","volume":"56","author":"Lackner","year":"2012","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.riam.2021.04.004_bib0315","doi-asserted-by":"crossref","first-page":"e01572","DOI":"10.1128\/AAC.01572-18","article-title":"Pharmacodynamic evaluation of rezafungin (CD101) against Candida auris in the neutropenic mouse invasive candidiasis model","volume":"62","author":"Lepak","year":"2018","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.riam.2021.04.004_bib0320","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1128\/AAC.04922-14","article-title":"Implication of Candida parapsilosis FKS1 and FKS2 mutations in reduced echinocandin susceptibility","volume":"59","author":"Mart\u00ed-Carrizosa","year":"2015","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.riam.2021.04.004_bib0325","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/mmy\/myv009","article-title":"Genotyping, extracellular compounds, and antifungal susceptibility testing of Trichosporon asahii isolated from Mexican patients","volume":"53","author":"Montoya","year":"2015","journal-title":"Med Mycol."},{"key":"10.1016\/j.riam.2021.04.004_bib0330","doi-asserted-by":"crossref","first-page":"e01692","DOI":"10.1128\/AAC.01692-19","article-title":"In Vitro activity of Ibrexafungerp, a novel glucan synthase inhibitor against Candida glabrata isolates with FKS mutations","volume":"63","author":"Nunnally","year":"2019","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.riam.2021.04.004_bib0335","doi-asserted-by":"crossref","first-page":"e00578","DOI":"10.1002\/mbo3.578","article-title":"Candida auris: A systematic review and meta-analysis of current updates on an emerging multidrug-resistant pathogen","volume":"7","author":"Osei Sekyere","year":"2018","journal-title":"Microbiology open."},{"key":"10.1016\/j.riam.2021.04.004_bib0340","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1093\/jac\/dks019","article-title":"Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey","volume":"67","author":"Pem\u00e1n","year":"2012","journal-title":"J Antimicrob Chemother."},{"key":"10.1016\/j.riam.2021.04.004_bib0345","doi-asserted-by":"crossref","first-page":"105807","DOI":"10.1016\/j.ijantimicag.2019.09.011","article-title":"Azole resistance mechanisms in Aspergillus: Update and recent advances","volume":"55","author":"P\u00e9rez-Cantero","year":"2020","journal-title":"Int J Antimicrob Agents."},{"key":"10.1016\/j.riam.2021.04.004_bib0350","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1086\/649858","article-title":"Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America","volume":"50","author":"Perfect","year":"2010","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.riam.2021.04.004_bib0355","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1128\/AAC.01530-08","article-title":"In vitro activity of isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing","volume":"53","author":"Perkhofer","year":"2009","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.riam.2021.04.004_bib0360","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1128\/AAC.45.10.2862-2864.2001","article-title":"In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans","volume":"45","author":"Pfaller","year":"2001","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.riam.2021.04.004_bib0365","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jof2040026","article-title":"New horizons antifungal therapy","volume":"2","author":"Pianalto","year":"2016","journal-title":"J Fungi."},{"key":"10.1016\/j.riam.2021.04.004_bib0370","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1093\/jac\/dkz078","article-title":"In vitro activity of olorofim (F901318) against clinical isolates of cryptic species of by EUCAST and CLSI methodologies","volume":"74","author":"Rivero-Menendez","year":"2019","journal-title":"J Antimicrob Chemother."},{"key":"10.1016\/j.riam.2021.04.004_bib0375","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.FUNK-0002-2016","article-title":"Antifungal drugs: The current armamentarium and development of new agents","volume":"4","author":"Robbins","year":"2016","journal-title":"Microbiol Spectr."},{"key":"10.1016\/j.riam.2021.04.004_bib0380","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.cmi.2014.07.013","article-title":"Burden of serious fungal infections in Spain","volume":"21","author":"Rodr\u00edguez-Tudela","year":"2015","journal-title":"Clin Microbiol Infect."},{"key":"10.1016\/j.riam.2021.04.004_bib0385","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1128\/AAC.00163-06","article-title":"In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts","volume":"50","author":"Sabatelli","year":"2006","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.riam.2021.04.004_bib0390","doi-asserted-by":"crossref","first-page":"e01627","DOI":"10.1128\/AAC.01627-16","article-title":"Safety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults","volume":"61","author":"Sandison","year":"2017","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.riam.2021.04.004_bib0395","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1128\/AAC.47.8.2404-2412.2003","article-title":"Candida albicans mutations in the ergosterol biosynthetic pathway and resistance to several antifungal agents","volume":"47","author":"Sanglard","year":"2003","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.riam.2021.04.004_bib0400","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1439-0507.2011.02165.x","article-title":"Species and susceptibility distribution of 1062 clinical yeast isolates to azoles, echinocandins, flucytosine and amphotericin B from a multicentre study","volume":"55","author":"Schmalreck","year":"2012","journal-title":"Mycoses."},{"key":"10.1016\/j.riam.2021.04.004_bib0405","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1021\/acsinfecdis.0c00117","article-title":"Unmasking the amphotericin B resistance mechanisms in Candida haemulonii species complex","volume":"6","author":"Silva","year":"2020","journal-title":"ACS Infect Dis."},{"key":"10.1016\/j.riam.2021.04.004_bib0410","doi-asserted-by":"crossref","first-page":"e219","DOI":"10.1371\/journal.pmed.0050219","article-title":"Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism","volume":"5","author":"Snelders","year":"2008","journal-title":"PLoS Med."},{"key":"10.1016\/j.riam.2021.04.004_bib0415","doi-asserted-by":"crossref","first-page":"S328","DOI":"10.1093\/mmy\/myz012","article-title":"Antifungal drugs: What brings the future?","volume":"57","author":"Van Daele","year":"2019","journal-title":"Med Mycol."},{"key":"10.1016\/j.riam.2021.04.004_bib0420","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.3109\/13693786.2010.499916","article-title":"Aspergillus species intrinsically resistant to antifungal agents","volume":"49","author":"Van Der Linden","year":"2011","journal-title":"Med Mycol."},{"key":"10.1016\/j.riam.2021.04.004_bib0425","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1128\/AAC.01715-18","article-title":"APX001 and other Gwt1 inhibitor prodrugs are effective in experimental Coccidioides immitis pneumonia","volume":"63","author":"Viriyakosol","year":"2019","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.riam.2021.04.004_bib0430","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1128\/AAC.49.8.3498-3500.2005","article-title":"In vitro synergistic interaction between amphotericin B and micafungin against Scedosporium spp","volume":"49","author":"Yustes","year":"2005","journal-title":"Antimicrob Agents Chemother."}],"container-title":["Revista Iberoamericana de Micolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130140621000309?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130140621000309?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T04:07:32Z","timestamp":1761106052000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130140621000309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S1130140621000309"],"URL":"https:\/\/doi.org\/10.1016\/j.riam.2021.04.004","relation":{},"ISSN":["1130-1406"],"issn-type":[{"value":"1130-1406","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antif\u00fangicos de uso sist\u00e9mico","name":"articletitle","label":"Article Title"},{"value":"Revista Iberoamericana de Micolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.riam.2021.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Asociaci\u00f3n Espa\u00f1ola de Micolog\u00eda.","name":"copyright","label":"Copyright"}]}}